These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24238398)

  • 1. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H; Gutschi M; Welzel J; Haas C
    J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
    [No Abstract]   [Full Text] [Related]  

  • 2. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
    D'Alonzo D; Glatz K
    Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
    [No Abstract]   [Full Text] [Related]  

  • 3. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 6. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
    Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
    J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
    Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
    J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
    [No Abstract]   [Full Text] [Related]  

  • 8. Community experience of vemurafenib for BRAF(V600) melanoma.
    Hersey P
    Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
    [No Abstract]   [Full Text] [Related]  

  • 9. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
    Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
    JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
    [No Abstract]   [Full Text] [Related]  

  • 13. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
    Wagle N; Emery C; Berger MF; Davis MJ; Sawyer A; Pochanard P; Kehoe SM; Johannessen CM; Macconaill LE; Hahn WC; Meyerson M; Garraway LA
    J Clin Oncol; 2011 Aug; 29(22):3085-96. PubMed ID: 21383288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
    Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
    JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BRAF mutation detection in metastatic melanoma].
    Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strides in melanoma announced: maximizing value comes next.
    Tuma RS
    J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
    [No Abstract]   [Full Text] [Related]  

  • 19. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
    Saint-Jean M; Quéreux G; Nguyen JM; Peuvrel L; Brocard A; Vallée A; Knol AC; Khammari A; Denis MG; Dréno B
    J Invest Dermatol; 2014 May; 134(5):1468-1470. PubMed ID: 24025553
    [No Abstract]   [Full Text] [Related]  

  • 20. Concerns regarding BRAF testing algorithm.
    Clark RR; Garioch JJ; Moncrieff MD
    Br J Dermatol; 2013 Nov; 169(5):1167-8. PubMed ID: 23855527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.